| scholarly article | Q13442814 |
| P2093 | author name string | Lisa Jerome | |
| Mark T Wagner | |||
| Ann T Mithoefer | |||
| Michael C Mithoefer | |||
| Rick Doblin | |||
| P2860 | cites work | Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication | Q22253031 |
| Oxytocin Modulates Neural Circuitry for Social Cognition and Fear in Humans | Q22255501 | ||
| Oxytocin increases trust in humans | Q28254266 | ||
| The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents | Q28257990 | ||
| Oxytocin is associated with human trustworthiness | Q28267939 | ||
| Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial | Q28377040 | ||
| A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine ("ecstasy") | Q28577690 | ||
| A method of conducting therapeutic sessions with MDMA. | Q30432617 | ||
| Pharmacotherapy for post-traumatic stress disorder - a systematic review and meta-analysis. | Q33266344 | ||
| Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects | Q33911701 | ||
| Gender differences in the subjective effects of MDMA. | Q33943522 | ||
| Clinician-administered PTSD scale: a review of the first ten years of research | Q33949505 | ||
| Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study | Q33956204 | ||
| What is a "mood stabilizer"? An evidence-based response | Q33974918 | ||
| Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care | Q34330469 | ||
| The epidemiology of posttraumatic stress disorder: what is the extent of the problem? | Q34331013 | ||
| Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder | Q34379429 | ||
| Ecstasy (MDMA) mimics the post-orgasmic state: impairment of sexual drive and function during acute MDMA-effects may be due to increased prolactin secretion | Q34404887 | ||
| The early history of "Ecstasy" | Q34482355 | ||
| The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity | Q34482688 | ||
| Oxytocin improves "mind-reading" in humans | Q34586095 | ||
| The relative efficacy of bona fide psychotherapies for treating post-traumatic stress disorder: a meta-analysis of direct comparisons | Q34720881 | ||
| Oxytocin shapes the neural circuitry of trust and trust adaptation in humans | Q34781060 | ||
| Effective psychotherapies for posttraumatic stress disorder: a review and critique. | Q34929778 | ||
| Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration. | Q34989613 | ||
| Do patients drop out prematurely from exposure therapy for PTSD? | Q35613612 | ||
| Neurocircuitry models of posttraumatic stress disorder and extinction: human neuroimaging research--past, present, and future | Q36571175 | ||
| Combining pharmacotherapy with cognitive behavioral therapy: traditional and new approaches | Q36639956 | ||
| Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults | Q37146495 | ||
| Pharmacotherapy of posttraumatic stress disorder: a review of meta-analyses and treatment guidelines. | Q37377379 | ||
| Common mental disorders in postconflict settings | Q38965688 | ||
| Posttraumatic stress disorder in an urban population of young adults: risk factors for chronicity | Q39238863 | ||
| The subjective effects of MDMA and mCPP in moderate MDMA users | Q43803511 | ||
| Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans | Q43841637 | ||
| Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram | Q43842041 | ||
| 3,4-Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H(2)(15)O]-PET in healthy humans | Q43842046 | ||
| Paced auditory serial-addition task: a measure of recovery from concussion | Q43974735 | ||
| The experimental use of psychedelic (LSD) psychotherapy | Q45078230 | ||
| Association of cardiovascular risk factors with mental health diagnoses in Iraq and Afghanistan war veterans using VA health care | Q45331383 | ||
| Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. | Q46985552 | ||
| Traumatic events and post-traumatic stress disorder in the community: prevalence, risk factors and comorbidity | Q47685826 | ||
| Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA-naïve healthy volunteers | Q48788983 | ||
| The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. | Q50921579 | ||
| Emotional processing of fear: exposure to corrective information. | Q51217642 | ||
| The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers. | Q51971591 | ||
| Post-traumatic stress reactions in children of war. | Q51985926 | ||
| Burden of medical illness in women with depression and posttraumatic stress disorder. | Q51995264 | ||
| Psychiatric consequences of "ethnic cleansing": clinical assessments and trauma testimonies of newly resettled Bosnian refugees | Q52017354 | ||
| Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population. | Q52289049 | ||
| Psychological and Cardiovascular Effects and Short-Term Sequelae of MDMA (“Ecstasy”) in MDMA-Naïve Healthy Volunteers | Q54297095 | ||
| Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations | Q71489898 | ||
| Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans | Q77921465 | ||
| Augmentation of sertraline with prolonged exposure in the treatment of posttraumatic stress disorder | Q79318217 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 439-52 | |
| P577 | publication date | 2011-04-01 | |
| P1433 | published in | Journal of Psychopharmacology | Q6295819 |
| P1476 | title | The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study | |
| P478 | volume | 25 |
| Q47777762 | (±)-MDMA and its enantiomers: potential therapeutic advantages of R(-)-MDMA. |
| Q93239810 | 3,4-Methylenedioxymethamphetamine (MDMA; ecstasy) use and transitions to injection drug use among street-involved youth |
| Q38829190 | 3,4-Methylenedioxymethamphetamine Increases Affiliative Behaviors in Squirrel Monkeys in a Serotonin 2A Receptor-Dependent Manner. |
| Q37347719 | 3,4-Methylenedioxymethamphetamine facilitates fear extinction learning |
| Q22299243 | 3,4-Methylenedioxymethamphetamine's (MDMA's) Impact on Posttraumatic Stress Disorder |
| Q58104849 | 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial |
| Q90357490 | 3,4-methylenedioxymethamphetamine (MDMA) impairs the extinction and reconsolidation of fear memory in rats |
| Q88573326 | 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial |
| Q24602762 | 3,4-methylenedioxymethamphetamine (MDMA): current perspectives |
| Q64070251 | A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy |
| Q46847604 | A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment |
| Q34309474 | A randomized, controlled pilot study of MDMA (± 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). |
| Q38192959 | A reconsideration and response to Parrott AC (2013) "Human psychobiology of MDMA or 'Ecstasy': an overview of 25 years of empirical research". |
| Q28484011 | A systematic prediction of multiple drug-target interactions from chemical, genomic, and pharmacological data |
| Q57177225 | A translational perspective on neural circuits of fear extinction: Current promises and challenges |
| Q30404060 | A window into the intoxicated mind? Speech as an index of psychoactive drug effects |
| Q34674320 | Acute Effects of the Novel Psychoactive Drug 2C-B on Emotions |
| Q33635662 | Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects. |
| Q36253278 | Acute effects of MDMA on autonomic cardiac activity and their relation to subjective prosocial and stimulant effects. |
| Q30544870 | Acute prosocial effects of oxytocin and vasopressin when given alone or in combination with 3,4-methylenedioxymethamphetamine in rats: involvement of the V1A receptor |
| Q38962662 | Altered Insula Connectivity under MDMA. |
| Q38015058 | Amphetamines, the pregnant woman and her children: a review |
| Q38160918 | Anxiolytic drug discovery: what are the novel approaches and how can we improve them? |
| Q64087722 | Aromatic Bromination Abolishes the Psychomotor Features and Pro-social Responses of MDMA ("Ecstasy") in Rats and Preserves Affinity for the Serotonin Transporter (SERT) |
| Q90120348 | Association between posttraumatic stress disorder and nonfatal drug overdose |
| Q64983258 | Augmentation of Extinction and Inhibitory Learning in Anxiety and Trauma-Related Disorders. |
| Q90400310 | Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline |
| Q37337904 | Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans: Lost in translation. |
| Q34535259 | Clinical applications of hallucinogens: A review |
| Q37458263 | Clinically Relevant Pharmacological Strategies That Reverse MDMA-Induced Brain Hyperthermia Potentiated by Social Interaction. |
| Q52300416 | Commentary on Coulson & Caulkins (2012): Optimizing drug scheduling. |
| Q52298270 | Commentary on Halpern et al. (2011): strengthening the case against functionally significant serotonergic neurotoxicity in human MDMA (ecstasy) users. |
| Q53449696 | Considering the context: social factors in responses to drugs in humans. |
| Q55007454 | Crime and Violence among MDMA Users in the United States. |
| Q52803481 | Current Perspective on MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder. |
| Q57176236 | Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine |
| Q34544993 | Decision-making in chronic ecstasy users: a systematic review. |
| Q47551565 | Depressive mood ratings are reduced by MDMA in female polydrug ecstasy users homozygous for the l-allele of the serotonin transporter |
| Q35965775 | Differences in the locomotor-activating effects of indirect serotonin agonists in habituated and non-habituated rats |
| Q43842167 | Differential effects of MDMA and methylphenidate on social cognition. |
| Q59131907 | Diminished positive affect and traumatic stress: A biobehavioral review and commentary on trauma affective neuroscience |
| Q47318737 | Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects. |
| Q93135591 | Do adjuvant interventions improve treatment outcome in adult patients with posttraumatic stress disorder receiving trauma-focused psychotherapy? A systematic review |
| Q41932270 | Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting |
| Q24620135 | Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study |
| Q50574947 | Effects of MDMA alone and after pretreatment with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin on pupillary light reflex. |
| Q64217983 | Effects of MDMA on attention to positive social cues and pleasantness of affective touch |
| Q53694581 | Effects of N, N-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression. |
| Q48463442 | Effects of Schedule I drug laws on neuroscience research and treatment innovation |
| Q45950720 | Effects of ecstasy on cooperative behaviour and perception of trustworthiness: a naturalistic study. |
| Q38966221 | Electrophysiological Actions of Synthetic Cathinones on Monoamine Transporters |
| Q34634128 | Evidence for chronically altered serotonin function in the cerebral cortex of female 3,4-methylenedioxymethamphetamine polydrug users |
| Q53091817 | Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. |
| Q48105789 | Experienced drug users assess the relative harms and benefits of drugs: a web-based survey |
| Q91130379 | Fear expression is suppressed by tyrosine administration |
| Q47675823 | Forbidden therapies: Santo Daime, ayahuasca, and the prohibition of entheogens in Western society |
| Q58803214 | Gene expression analysis indicates reduced memory and cognitive functions in the hippocampus and increase in synaptic reorganization in the frontal cortex 3 weeks after MDMA administration in Dark Agouti rats |
| Q47312691 | High ambient temperature facilitates the acquisition of 3,4-methylenedioxymethamphetamine (MDMA) self-administration |
| Q34420092 | History and future of the Multidisciplinary Association for Psychedelic Studies (MAPS). |
| Q34359604 | Human psychobiology of MDMA or 'Ecstasy': an overview of 25 years of empirical research |
| Q90667604 | Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature |
| Q38652284 | Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA). |
| Q36421673 | Intimate insight: MDMA changes how people talk about significant others |
| Q24630561 | Is ecstasy an "empathogen"? Effects of ±3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others |
| Q38986358 | Keto amphetamine toxicity-focus on the redox reactivity of the cathinone designer drug mephedrone. |
| Q47206849 | Key interindividual determinants in MDMA pharmacodynamics. |
| Q37262799 | LSD Acutely Impairs Fear Recognition and Enhances Emotional Empathy and Sociality |
| Q26799231 | Legal highs: staying on top of the flood of novel psychoactive substances |
| Q26859367 | Lost in translation: preclinical studies on 3,4-methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans |
| Q56961628 | MDMA |
| Q37149027 | MDMA (3,4-Methylenedioxymethamphetamine) Analogues as Tools to Characterize MDMA-Like Effects: An Approach to Understand Entactogen Pharmacology |
| Q93220727 | MDMA Increases Cooperation and Recruitment of Social Brain Areas When Playing Trustworthy Players in an Iterated Prisoner's Dilemma |
| Q34325163 | MDMA alters emotional processing and facilitates positive social interaction |
| Q47901966 | MDMA does not alter responses to the Trier Social Stress Test in humans |
| Q50592804 | MDMA enhances "mind reading" of positive emotions and impairs "mind reading" of negative emotions. |
| Q34375625 | MDMA enhances emotional empathy and prosocial behavior |
| Q46749663 | MDMA enhances hippocampal-dependent learning and memory under restrictive conditions, and modifies hippocampal spine density |
| Q92483926 | MDMA enhances pleasantness of affective touch |
| Q21558551 | MDMA for the treatment of mood disorder: all talk no substance? |
| Q59068914 | MDMA keeps severe stress at bay |
| Q91839166 | MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials |
| Q102379345 | MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study |
| Q35626948 | Manganese-enhanced magnetic resonance imaging reveals differential long-term neuroadaptation after methamphetamine and the substituted cathinone 4-methylmethcathinone (mephedrone). |
| Q39548034 | Measuring the subjective: revisiting the psychometric properties of three rating scales that assess the acute effects of hallucinogens. |
| Q55043421 | Methylenedioxymethamphetamine (MDMA, ‘Ecstasy’): Neurodegeneration versus Neuromodulation. |
| Q51482161 | Neurochemical binding profiles of novel indole and benzofuran MDMA analogues. |
| Q26770106 | Neuroimaging in moderate MDMA use: A systematic review |
| Q59791313 | Neuroscience Informed Prolonged Exposure Practice: Increasing Efficiency and Efficacy Through Mechanisms |
| Q38191529 | New phenethylamines in Europe |
| Q48190285 | No major role of norepinephrine transporter gene variations in the cardiostimulant effects of MDMA. |
| Q37422671 | Nonlinear pharmacokinetics of (+/-)3,4-methylenedioxymethamphetamine (MDMA) and its pharmacodynamic consequences in the rat. |
| Q34521723 | Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. |
| Q37184290 | Oxytocin receptor gene variation predicts subjective responses to MDMA. |
| Q55264971 | Oxytocin receptor gene variations and socio-emotional effects of MDMA: A pooled analysis of controlled studies in healthy subjects. |
| Q38442124 | Oxytocin: parallel processing in the social brain? |
| Q28070159 | PTSD: from neurobiology to pharmacological treatments |
| Q37113859 | Perspectives on zebrafish models of hallucinogenic drugs and related psychotropic compounds |
| Q22305514 | Pharmacological enhancement of exposure-based treatment in PTSD: a qualitative review |
| Q36851442 | Pharmacological examination of trifluoromethyl ring-substituted methcathinone analogs |
| Q27006437 | Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders |
| Q26776489 | Post-traumatic stress disorder |
| Q93181348 | Post-traumatic stress disorder: a state-of-the-art review of evidence and challenges |
| Q89774560 | Posttraumatic Growth After MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder |
| Q58213889 | Posttraumatic Stress Disorder: An Integrated Overview of the Neurobiological Rationale for Pharmacology |
| Q47963200 | Progress and promise for the MDMA drug development program |
| Q41307521 | Prosocial effects of MDMA: A measure of generosity. |
| Q55381227 | Psilocybin and MDMA reduce costly punishment in the Ultimatum Game. |
| Q34493217 | Psychedelic medicine: a re-emerging therapeutic paradigm |
| Q57309250 | Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development |
| Q30359998 | Psychedelics |
| Q89091482 | Psychedelics Promote Structural and Functional Neural Plasticity |
| Q47410020 | Psychedelics and reconsolidation of traumatic and appetitive maladaptive memories: focus on cannabinoids and ketamine |
| Q29398415 | Psychoactive Substances and the English Language: “Drugs,” Discourses, and Public Policy |
| Q24201806 | Psychological therapies for chronic post-traumatic stress disorder (PTSD) in adults |
| Q47697448 | Recreational 3,4-methylenedioxy-N-methylamphetamine (MDMA) or 'ecstasy' and self-focused compassion: Preliminary steps in the development of a therapeutic psychopharmacology of contemplative practices |
| Q58757402 | Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study |
| Q91665835 | Regular MDMA use is associated with decreased risk of drug injection among street-involved youth who use illicit drugs |
| Q43740653 | Reply to the letter to the editor by H Chabrol |
| Q48420021 | Research on psychedelic substances |
| Q34645841 | Residual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs |
| Q90318457 | Reviewing the Potential of Psychedelics for the Treatment of PTSD |
| Q38819567 | Safety pharmacology of acute MDMA administration in healthy subjects. |
| Q90400382 | Self-Rated Effectiveness of Microdosing With Psychedelics for Mental and Physical Health Problems Among Microdosers |
| Q47769685 | Self-experimentations with psychedelics among mental health professionals: LSD in the former Czechoslovakia |
| Q47662199 | Separating the agony from ecstasy: R(-)-3,4-methylenedioxymethamphetamine has prosocial and therapeutic-like effects without signs of neurotoxicity in mice |
| Q38600048 | Serotonin and brain function: a tale of two receptors |
| Q34640595 | Shaping the renaissance of psychedelic research |
| Q48292506 | Should addiction researchers be interested in psychedelic science? |
| Q45053309 | Single oral doses of (±) 3,4-methylenedioxymethamphetamine ('Ecstasy') produce lasting serotonergic deficits in non-human primates: relationship to plasma drug and metabolite concentrations |
| Q60619766 | Social Cognition |
| Q37899850 | Social, policy, and public health perspectives on new psychoactive substances. |
| Q27016155 | Targeting memory processes with drugs to prevent or cure PTSD |
| Q47640031 | The 21st century psychedelic renaissance: heroic steps forward on the back of an elephant |
| Q34659485 | The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level-Dependent Resting State Functional Connectivity |
| Q34502080 | The Psychopharmacology of ±3,4 Methylenedioxymethamphetamine and its Role in the Treatment of Posttraumatic Stress Disorder |
| Q28806840 | The association of psychedelic use and opioid use disorders among illicit users in the United States |
| Q34392399 | The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories |
| Q38937390 | The effects of MDMA on socio-emotional processing: Does MDMA differ from other stimulants? |
| Q49357192 | The hidden therapist: evidence for a central role of music in psychedelic therapy |
| Q51339121 | The intersection of structurally traumatized communities and substance use treatment: Dominant discourses and hidden themes. |
| Q28240897 | The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humans |
| Q34495787 | The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): Controlled studies in humans and laboratory animals. |
| Q41254417 | Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy |
| Q38023813 | Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypotheses |
| Q89716254 | Translating molecular and neuroendocrine findings in posttraumatic stress disorder and resilience to novel therapies |
| Q59132161 | Treating PTSD: A Review of Evidence-Based Psychotherapy Interventions |
| Q34523797 | Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: A preliminary meta-analysis and comparison to prolonged exposure therapy |
| Q38687081 | Why Psychiatry Needs 3,4-Methylenedioxymethamphetamine: A Child Psychiatrist's Perspective |
Search more.